These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21305347)

  • 1. Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.
    Kloska A; Jakóbkiewicz-Banecka J; Narajczyk M; Banecka-Majkutewicz Z; Węgrzyn G
    Metab Brain Dis; 2011 Mar; 26(1):1-8. PubMed ID: 21305347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids.
    Moskot M; Jakóbkiewicz-Banecka J; Kloska A; Smolińska E; Mozolewski P; Malinowska M; Rychłowski M; Banecki B; Węgrzyn G; Gabig-Cimińska M
    Sci Rep; 2015 Mar; 5():9378. PubMed ID: 25797591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway.
    Jakóbkiewicz-Banecka J; Piotrowska E; Narajczyk M; Barańska S; Wegrzyn G
    J Biomed Sci; 2009 Mar; 16(1):26. PubMed ID: 19272193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease.
    Dziedzic D; Wegrzyn G; Jakóbkiewicz-Banecka J
    Eur J Hum Genet; 2010 Feb; 18(2):200-5. PubMed ID: 19690584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones.
    Arfi A; Richard M; Gandolphe C; Scherman D
    J Inherit Metab Dis; 2010 Feb; 33(1):61-7. PubMed ID: 20084460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic genistein derivatives as modulators of glycosaminoglycan storage.
    Kloska A; Narajczyk M; Jakóbkiewicz-Banecka J; Grynkiewicz G; Szeja W; Gabig-Cimińska M; Węgrzyn G
    J Transl Med; 2012 Jul; 10():153. PubMed ID: 22846663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses.
    Piotrowska E; Jakóbkiewicz-Banecka J; Barańska S; Tylki-Szymańska A; Czartoryska B; Wegrzyn A; Wegrzyn G
    Eur J Hum Genet; 2006 Jul; 14(7):846-52. PubMed ID: 16670689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.
    Kingma SD; Wagemans T; IJlst L; Wijburg FA; van Vlies N
    J Inherit Metab Dis; 2014 Sep; 37(5):813-21. PubMed ID: 24699889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice.
    Malinowska M; Wilkinson FL; Bennett W; Langford-Smith KJ; O'Leary HA; Jakobkiewicz-Banecka J; Wynn R; Wraith JE; Wegrzyn G; Bigger BW
    Mol Genet Metab; 2009 Nov; 98(3):235-42. PubMed ID: 19632871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients.
    Malinová V; Węgrzyn G; Narajczyk M
    JIMD Rep; 2012; 5():21-5. PubMed ID: 23430913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome.
    Canals I; Benetó N; Cozar M; Vilageliu L; Grinberg D
    Sci Rep; 2015 Sep; 5():13654. PubMed ID: 26347037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and Gene Expression Response to the Combination of Genistein and Kaempferol in the Treatment of Mucopolysaccharidosis Type I.
    Węsierska M; Kloska A; Medina DL; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Radzińska M; Moskot M; Malinowska M
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive evaluation of pathogenic protein accumulation in fibroblasts from all subtypes of Sanfilippo disease patients.
    Wiśniewska K; Rintz E; Żabińska M; Gaffke L; Podlacha M; Cyske Z; Węgrzyn G; Pierzynowska K
    Biochem Biophys Res Commun; 2024 Nov; 733():150718. PubMed ID: 39305572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
    Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients.
    Piotrowska E; Jakóbkiewicz-Banecka J; Tylki-Szymanska A; Liberek A; Maryniak A; Malinowska M; Czartoryska B; Puk E; Kloska A; Liberek T; Baranska S; Wegrzyn A; Wegrzyn G
    Curr Ther Res Clin Exp; 2008 Apr; 69(2):166-79. PubMed ID: 24692796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycosaminoglycans and mucopolysaccharidosis type III.
    Jakobkiewicz-Banecka J; Gabig-Ciminska M; Kloska A; Malinowska M; Piotrowska E; Banecka-Majkutewicz Z; Banecki B; Wegrzyn A; Wegrzyn G
    Front Biosci (Landmark Ed); 2016 Jun; 21(7):1393-409. PubMed ID: 27100513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genistein in Sanfilippo disease: a randomized controlled crossover trial.
    de Ruijter J; Valstar MJ; Narajczyk M; Wegrzyn G; Kulik W; Ijlst L; Wagemans T; van der Wal WM; Wijburg FA
    Ann Neurol; 2012 Jan; 71(1):110-20. PubMed ID: 22275257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine Fibroblasts and Primary Hepatocytes as Tools When Studying the Efficacy of Potential Therapies for Mucopolysaccharidosis Type I.
    Węsierska M; Nowicka W; Kloska A; Jakóbkiewicz-Banecka J; Malinowska M
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
    Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
    Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.